Infectious Complications After Tocilizumab in Patients with COVID: A Real-World Experience

Mostrar otras versiones (1)

INTRODUCTION: Controversies remain regarding the safety of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this study, we seek to describe the infectious complications after tocilizumab in COVID patients and determine the related risk factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongli, Niu, Chengu, Elkhapery, Ahmed, Zhu, Kaiwen, Nair, Lakshmi G., Anjum, Zauraiz, Iyer, Charoo, Faisal, Hafsa, Chow, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Greater Baltimore Medical Center 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924625/
https://www.ncbi.nlm.nih.gov/pubmed/36817306
http://dx.doi.org/10.55729/2000-9666.1141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924625/
https://www.ncbi.nlm.nih.gov/pubmed/36817306
http://dx.doi.org/10.55729/2000-9666.1141

Ejemplares similares